News

Active Biotech’s presentation at Solebury Trout European Biotech Investor Days 2021

April 8, 2021

Number of shares and votes in Active Biotech

March 31, 2021

Number of shares and votes in Active Biotech

March 2, 2021

Active Biotech Year-end report January – December 2020

February 11, 2021

Active Biotech enters into a manufacturing agreement with Famar Health Care Services for new formulation of Laquinimod

February 4, 2021

Active Biotech’s rights issue heavily oversubscribed

January 26, 2021

Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue

January 7, 2021

Active Biotech publishes prospectus and certain new financial information included in the prospectus

January 5, 2021

Redeye initiates coverage of Active Biotech, see analysis

December 14, 2020

Active Biotech Receive Milestone Payment From NeoTX

December 11, 2020

Active Biotech’s presentation at Life Science Day 2020 (in Swedish)

December 2, 2020

Active Biotech’s nomination committee appointed

December 1, 2020

Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue

November 30, 2020

Active Biotech announces the final terms of the rights issue

November 25, 2020

Active Biotech updates its clinical strategy and projected milestones

November 24, 2020

Invitation to Active Biotech’s virtual capital markets day

November 6, 2020

Notice of extraordinary general meeting in Active Biotech

November 5, 2020

Active Biotech carries out rights issue

November 5, 2020

Active Biotech Interim report January – September 2020

November 5, 2020

Active Biotech Interim Report January – June 2020

August 6, 2020

Active Biotech announces first patient dosed in phase 1b/2a study of tasquinimod use in treatment of multiple myeloma

August 3, 2020

Tasquinimod demonstrates potent anti-tumor activity in experimental models for multiple myeloma. Data will be presented at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress Meeting, taking place June 11-21 2020

June 12, 2020

Presentation – new direction

June 3, 2020

New pre-clinical data on laquinimod in an experimental autoimmune uveitis model has been published as an abstract in the Journal of Immunology. May 1, 2020, 204 (1 Supplement) 150.18.

June 3, 2020

Active Biotech provides status update in the portfolio projects

June 3, 2020

Annual General Meeting of Active Biotech AB

May 19, 2020

Annual Report 2019

April 24, 2020

Notice of annual general meeting of shareholders on Tuesday, May 19, 2020

April 20, 2020

Active Biotech AB – Year-end report January – December 2019

February 6, 2020

Active Biotech announces new direction

February 5, 2020

Active Biotech’s election committee appointed

November 19, 2019

Active Biotech Interim report January – September 2019

November 14, 2019

New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

November 5, 2019

Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

October 28, 2019

New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders

September 23, 2019

Active Biotech AB: Interim report January – June 2019

August 8, 2019

The Annual General Meeting of Active Biotech was held on May 23, 2019

May 24, 2019

The Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference “American Academy of Neurology – AAN” in Philadelphia, PA, on May 6 2019

May 3, 2019

The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board

May 2, 2019

Annual Report 2018 Active Biotech AB (publ)

April 26, 2019

Active Biotech AB – Interim report January – March 2019

April 25, 2019

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

April 24, 2019

Active Biotech completes sale of property

April 5, 2019

An Extraordinary General Meeting of Active Biotech AB was held on April 4, 2019

April 5, 2019

Active Biotech has entered into an agreement regarding sale of the Company’s property – extraordinary general meeting on April 4, 2019

March 13, 2019

Active Biotech Year-end report January – December 2018

February 14, 2019

Active Biotech’s partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

February 11, 2019

Active Biotech has received an indicative bid for the property in Lund – the Board is positive

February 1, 2019

Active Biotech provides updated information about the company’s financial position

December 10, 2018

Interim report January – September 2018

November 15, 2018